JP6389124B2 - Ｒｅｔ蛋白質のｃ−末端ドメインを含む融合蛋白質及びその診断マーカーとしての用途 - Google Patents

Ｒｅｔ蛋白質のｃ−末端ドメインを含む融合蛋白質及びその診断マーカーとしての用途 Download PDF

Info

Publication number
JP6389124B2
JP6389124B2 JP2014538724A JP2014538724A JP6389124B2 JP 6389124 B2 JP6389124 B2 JP 6389124B2 JP 2014538724 A JP2014538724 A JP 2014538724A JP 2014538724 A JP2014538724 A JP 2014538724A JP 6389124 B2 JP6389124 B2 JP 6389124B2
Authority
JP
Japan
Prior art keywords
fusion
ret
kif5b
seq
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014538724A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015504299A5 (enExample
JP2015504299A (ja
Inventor
ヨン−ソク・ジュ
ジョン−スン・セオ
ウン−ヒ・キム
Original Assignee
マクロジェン・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マクロジェン・インコーポレーテッド filed Critical マクロジェン・インコーポレーテッド
Publication of JP2015504299A publication Critical patent/JP2015504299A/ja
Publication of JP2015504299A5 publication Critical patent/JP2015504299A5/ja
Application granted granted Critical
Publication of JP6389124B2 publication Critical patent/JP6389124B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/205—Aptamer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2014538724A 2011-10-31 2012-10-31 Ｒｅｔ蛋白質のｃ−末端ドメインを含む融合蛋白質及びその診断マーカーとしての用途 Active JP6389124B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161553483P 2011-10-31 2011-10-31
US61/553,483 2011-10-31
US13/663,565 2012-10-30
US13/663,565 US10023855B2 (en) 2011-10-31 2012-10-30 Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker
PCT/KR2012/009056 WO2013066047A1 (en) 2011-10-31 2012-10-31 Fusion protein comprising c-terminal domain of ret protein and use thereof as a diagnosing marker

Publications (3)

Publication Number Publication Date
JP2015504299A JP2015504299A (ja) 2015-02-12
JP2015504299A5 JP2015504299A5 (enExample) 2015-12-03
JP6389124B2 true JP6389124B2 (ja) 2018-09-12

Family

ID=48192340

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014538724A Active JP6389124B2 (ja) 2011-10-31 2012-10-31 Ｒｅｔ蛋白質のｃ−末端ドメインを含む融合蛋白質及びその診断マーカーとしての用途

Country Status (5)

Country Link
US (1) US10023855B2 (enExample)
EP (1) EP2773673B1 (enExample)
JP (1) JP6389124B2 (enExample)
KR (2) KR101625139B1 (enExample)
WO (1) WO2013066047A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013028817A1 (en) 2011-08-23 2013-02-28 Foundation Medicine , Inc. Novel kif5b-ret fusion molecules and uses thereof
JP6513567B2 (ja) * 2012-09-07 2019-05-15 エクセリクシス， インク． 肺腺癌の治療で使用するためのｍｅｔ、ｖｅｇｆｒ、およびｒｅｔの阻害剤
PL2902029T3 (pl) 2012-09-25 2019-01-31 Chugai Seiyaku Kabushiki Kaisha Inhibitor RET
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
AR107912A1 (es) 2016-03-17 2018-06-28 Blueprint Medicines Corp Inhibidores de ret
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
EP3674325A4 (en) * 2017-08-21 2021-11-03 Taiho Pharmaceutical Co., Ltd. FUSION PROTEIN OF DCTN1 PROTEIN WITH RET PROTEIN
SG11202009681YA (en) 2018-04-03 2020-10-29 Blueprint Medicines Corp Ret inhibitor for use in treating cancer having a ret alteration
WO2021243192A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
CR20220666A (es) 2020-05-29 2023-05-05 Blueprint Medicines Corp Composiciones farmacéuticas de pralsetinib

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126918A (en) 1996-05-08 2007-06-03 Biogen Idec Inc Ret ligand (retl) for stimulating neural and renal growth
AU2001281136A1 (en) 2000-08-04 2002-02-18 Board Of Regents, The University Of Texas System Detection and diagnosis of smoking related cancers
AU2004286845A1 (en) 2003-10-30 2005-05-19 Tufts-New England Medical Center Prenatal diagnosis using cell-free fetal DNA in amniotic fluid
JPWO2007049624A1 (ja) 2005-10-24 2009-04-30 武田薬品工業株式会社 癌の予防・治療剤
US20110195072A1 (en) 2006-09-12 2011-08-11 Anne Boulay Non-neuroendocrine cancer therapy
JPWO2012014795A1 (ja) 2010-07-26 2013-09-12 アステラス製薬株式会社 新規ｒｅｔ融合体の検出法
WO2013018882A1 (ja) 2011-08-04 2013-02-07 独立行政法人国立がん研究センター Ｋｉｆ５ｂ遺伝子とｒｅｔ遺伝子との融合遺伝子、並びに該融合遺伝子を標的としたがん治療の有効性を判定する方法
WO2013028817A1 (en) * 2011-08-23 2013-02-28 Foundation Medicine , Inc. Novel kif5b-ret fusion molecules and uses thereof

Also Published As

Publication number Publication date
US10023855B2 (en) 2018-07-17
WO2013066047A1 (en) 2013-05-10
KR101625139B1 (ko) 2016-05-31
EP2773673B1 (en) 2019-12-04
KR20160052751A (ko) 2016-05-12
JP2015504299A (ja) 2015-02-12
KR101660235B1 (ko) 2016-09-27
KR20140092846A (ko) 2014-07-24
US20130116280A1 (en) 2013-05-09
EP2773673A4 (en) 2015-03-18
EP2773673A1 (en) 2014-09-10

Similar Documents

Publication Publication Date Title
JP2015504299A (ja) Ｒｅｔ蛋白質のｃ−末端ドメインを含む融合蛋白質及びその診断マーカーとしての用途
US10822622B2 (en) Methods for treating cells containing fusion genes
Wang et al. BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance
Li et al. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis
Miyanaga et al. Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing
Scrima et al. The nonreceptor-type tyrosine phosphatase PTPN13 is a tumor suppressor gene in non–small cell lung cancer
CN103764676A (zh) Kif5b基因和ret基因的融合基因、以及以该融合基因为目标的判断癌症治疗有效性的方法
Cazes et al. The MST1R/RON tyrosine kinase in cancer: oncogenic functions and therapeutic strategies
JP2020202839A (ja) タンパク質キナーゼ阻害剤に対する感受性予測用バイオマーカー及びその用途
JP2015521050A (ja) 肺がん転移の診断、予後診断および処置のための方法
CN104619841A (zh) Cep55基因与ret基因的融合基因
JP2016539625A (ja) 乳がんに由来する骨の転移がんの予後診断および処置のための方法
Xing et al. Analysis of mutations in primary and metastatic synovial sarcoma
Biswas et al. Genomic profiling of multiple sequentially acquired tumor metastatic sites from an “exceptional responder” lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response
EP3778644A2 (en) Fgfr-tacc fusion proteins and methods thereof
Ning et al. Enhancer reprogramming reveals the tumorigenic role of PTPRZ1 in lung squamous cell carcinoma
Zhang et al. Tumor suppressor SLC9A2 inhibits colorectal cancer metastasis and reverses immunotherapy resistance by suppressing angiogenesis
WO2022159852A1 (en) Methods and compositions for treating adenoid cystic carcinoma
EP2894169A1 (en) Fusion protein comprising axl and composition for treating cancer comprising same
US20190062846A1 (en) Compositions and methods for screening pediatric gliomas and methods of treatment thereof
Golenar Oncogenic Activity of Met Receptor Tyrosine Kinase Exon 14 Deletion Variant
Carli The function of Doublecortin-Like kinase 1 (DCLK1) in gastric cancer
니티 Effect of PAIP1 expression on metastatic potential and its prognostic significance in oral squamous cell carcinoma
Yu The Role of Long Non-Coding RNA DANCR in Non-Small Cell Lung Cancer
Justine The Role of Long Non-coding RNA DANCR in Non-small Cell Lung Cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151009

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170403

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180330

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180723

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180816

R150 Certificate of patent or registration of utility model

Ref document number: 6389124

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250